Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Liabilities (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Other Non-Current Liabilities data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 44.56% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 44.56%, while the annual FY2025 figure was $2.1 million, 44.56% down from the prior year.
  • Other Non-Current Liabilities reached $2.1 million in Q4 2025 per TGTX's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.8 million in Q4 2024 and bottomed at $243000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.7 million, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 61.62% in 2021, then soared 961.62% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $360000.0 in 2021, then plummeted by 32.5% to $243000.0 in 2022, then skyrocketed by 46.91% to $357000.0 in 2023, then skyrocketed by 961.62% to $3.8 million in 2024, then plummeted by 44.56% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.2 million in Q2 2025.